Firstly described at the end of nineteenth century, endometriosis remains an enigmatic disease, from etiopathogenesis to specific markers of diagnosis and its ability to associate with malignancies. Our review has been designed from a historical perspective and steps up to an updated understanding of the disease, facilitated by relatively recent molecular and genetic progresses. Although the histopathological diagnosis is relatively simple, the therapy is difficult or ineffective. Experimental models have been extremely useful as they reproduce the human disease and allow the testing of different potential modulators or treatment options. Due to molecular resemblance to carcinogenesis, applications of anti-cancer agents are currently under scrutiny. The desired goal of an efficient therapy against symptomatic disease, along with associated infertility and malignancies, needs a deeper insight into the complex mechanisms involved in endometriosis initiation, development, and progression. Current trends in genomic and proteomic approaches are useful for a more accurate classification and for the identification of new therapeutic targets.
appearance, to cystic, red implants, or petechiae, vesicles, nodules, and, sometimes, polyps, depending on their location, duration, and association with fibrous adhesions [13] .
A combined anatomical and histopathological classification recognizes three main types of endometriosis: endometrioma, peritoneal, and deep infiltrative lesions [9] .
Endometrial cysts or endometriomas usually involve the ovaries, exhibit bilateral location in around one third of cases and develop until almost completely replacing the ovarian parenchyma [13] . They are most commonly associated with fibrous walls, adherences to neighboring structures, and usually chocolate-colored inspissated or semifluid content [13] . If larger than 15 cm in diameter or associated with polypoid projections or solid areas, a developing neoplasm should be considered [13] .
Peritoneal endometriosis may involve (in decreasing order of frequency): ovaries (30%), uterosacral and large ligaments (18-24%), fallopian tubes (20%), pelvic peritoneum, Douglas pouch, and gastro-intestinal tract [5, 6] .
Deep infiltrative endometriosis has been identified in 30-40% of patients diagnosed with endometriosis [5] , involving pelvis and gastrointestinal tract [6] .
Histopathological findings have been based on the identification of endometrial glands surrounded by characteristic cellular stroma (Fig. 1A) , registering an analogous pattern to the eutopic endometrial cycle.
Although histopathological diagnosis can be relatively simply reached, the microscopic differentials with ovarian endosalpingiosis [13] , a lesion frequently overdiagnosed as endometriosis, has to be made. This may be achieved by the identification of a stromal inflammatory infiltrate, containing variable amount of lymphocytes, a reduced number of other inflammatory cells, with evident hemosiderin-laden macrophages (Fig. 1B) , as proof of a cyclic evolution of the ectopic tissue, although a ceroid pigment may occasionally confer a pseudoxanthoma appearance to these cells [13] . Rarely, benign cystic lesions or even well differentiated adenocarcinomas may be included in the differential diagnosis. Currently, immunohistochemical profile may be useful, by CD10 strong stromal positivity, ERb and PR-A variable epithelial and stromal positivity, along with Bcl-2 and Ki-67 epithelial and stromal positivity correlated to the size of the implant, supplementing the histological characteristics exhibited in routine staining [14] .
The accumulation of data on endometriosis has been facilitated by comparative studies between native and experimental disease, due to a close resemblance of both laparoscopic findings and microscopic patterns demonstrated between animal models and their corresponding human disease [15] . www.fhc.viamedica.pl
Markers for diagnosis
The specific markers of endometriosis may be classified into three main categories ( [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] , autoantibodies [58, 59] , and environmental contaminants [60] . The diagnostic value of some of these markers has been quantified and, as a result, two peritoneal and/or serum cytokines may be useful in the diagnosis of endometriosis, such as increased serum IL-6 (threshold of 2 pg/ml) [49] , and serum or peritoneal fluid TNF-a (threshold of 15 pg/ml) [49] , although conflicting results are reported in possible correlation with disease stage, location, endometrial cycle phase, control groups, and assay type [49] .
The endometrial and biochemical-endometrial markers are considered as stromal [61, 62] , glandular [62] [63] [64] , neuronal [65] , proteolytic enzymes and their specific inhibitors [28-31, [66] [67] [68] [69] [70] , adhesion molecules [34, 62, [71] [72] [73] [74] , osteopontin [75] , hormonal receptors [38, 39, [76] [77] [78] [79] [80] , and mesenchymal stem cells [81] [82] [83] [84] [85] .
Genetic markers belong to variable categories, such as: oxidative stress genes [86] , tumor suppressor genes [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] , oncogenes [90, [99] [100] [101] [102] [103] , regulatory genes [104, 105] , DNA repair genes [93] , chromosomal aberrations or amplifications [106] [107] [108] , loss of heterozygosity [87, 107, 109] , genetic polymorphism of variable genes [107, [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] , and genome-wide alterations [120, 121] .
The prospective clinical validation of these markers and determination of their clinical utility may lead to the development of a successful commercial test for endometriosis diagnosis.
Past to rediscovered etiopathogenic theories and recent contributions

Short overview -historical hallmarks
Endometriosis is considered as the "theories disease", taking into account numerous past and modern etiopathogenic hypotheses which have been launched during a long period of attempts to explain its nature [4, 9] (Fig. 2) .
According to the past theories, endometriosis may result by in situ development from germinal ovarian epithelium [122] , from embryonic mesonephric elements (Wolffian knob and Wolffian duct) [9] , or from paramesonephric (Müllerian ducts) remnants [3, 9, 123] .
Other hypotheses are those of metaplastic processes, as coelomic metaplasia [9, [124] [125] [126] , or metaplasia of the peritoneal or ovarian tissue [127, 128] , or metaplasia of the peritoneal serosa cuff initiated by inflammation [9, 129] or by hormonal stimulation [130] . The possibility of metaplasia development, by differentiation of mesenchymal cells (omnipotent blastema) activated by substances released by degenerating endometrium eliminated into the abdominal cavity, has been also proposed [131, 132] . A secondary Müllerian system development is suggested by another theory launched in 70s [128] .
As a result of further studies and epidemiologic characteristics, the hypothesis of transplantation, due to retrograde menstruation [9, 133, 134] , or to mechanical transplantation [9] has been later developed.
In order to find a possible mechanism for implants' development in other locations which could not be ex- www.fhc.viamedica.pl plained by previous hypotheses, benign lymphogenous or hematogenous metastasis (hystero-adenosis metastatica) [135, 136] , or combinations of in situ development with endometrial transplantation and implantation or induction theory [132, 137] have been later proposed.
Mechanisms and dynamics of endometriosis: current concepts
Considering the wide distribution of endometriosis locations within human organism, modern theories try to combine the effect of multiple contributors, as multi-factorial, multi-compartmental pathogenic phenomena, associated with epiphenomena, as sequelae of the primary lesions, such as estrogen dependence [138] , genetic susceptibility [139] , and the possibility of direct spread by "transplantation" [9] . These processes are added to the incapacity of the immune system to neutralize ectopic endometrial cells [140] [141] [142] , or the contextual environmental factors to intervene in the process, and the occurrence of congenital defects, such as atretic hymen. The last but not the least, the most plausible pathogenic mechanism is the involvement of stem cells as the main "culprits" in the process of ectopic implantation via retrograde menses.
Retrograde menstruation and stem cells: a new perspective of an old theory
The currently agreed endometriosis pathogenic mechanism is that of retrograde menstruation, via fallopian tubes, a theory that had been launched by Sampson, as early as in 20's. There are numerous elements that plead for the accuracy of this theory, as following: the retrograde menstruation is quite frequent, being estimated that viable endometrial cells may be found in peritoneal cavity in about 76-90% of women, in non-menstrual periods of time or in peritoneum, during menstruation or immediately after this phase [143] . Furthermore, the blocking of evacuation of the menstrual blood results in extended endometriosis [143] . Moreover, an endometriosis onset at prepuberty is quite rare [143] .
The counterarguments of the involvement of this mechanism are provided by evidences that endometriosis may appear in areas which are inaccessible to menstrual reflux, including extra-peritoneal locations, a finding that may support lymphatic or hematogenous cells migration [4] .
Relatively recent data have demonstrated the occurrence of mesenchymal stem cells and progenitor endometrial cells in endometriosis and their possible evolution toward differentiation into nine cellular lines: adipocytic, osteogenic, cardiomyocytic, respiratory epithelium, neurocytic, myocytic, endothelial, pancreatic, and hepatic types [144] .
Although a key role is attributed to the stem cells reflux into the peritoneal cavity, the microenvironment factors that stimulate stem cells' functions and allow the development of endometriotic implants are very important in the retrograde menstruation mechanism.
Role of metalloproteinases
MMPs are involved in endometrial turnover and its pathology [145] . In endometriosis, after the attachment to the ectopic sites, the epithelial endometrial cells invade the extracellular matrix. It has been demonstrated that this process occurs with the involvement of MMPs, their high concentration in the peritoneal fluid being stimulated by TNF-a and IL-1 [146] . Concomitantly, TNF-a inhibits TIMP-1 and TIMP-2 [147] [66] , VEGF/MMP-3/uPA [68] , VEGF/ /MMP-2/CD44/Ki67 [69] , PAI/TIMP-1 [70] , and IL-1/ /MMP-1 [67] are characteristic features of endometriosis (Table 1) . (Fig. 3) .
Inflammation: cells and cytokines
NK cells have been also incriminated in endometriosis pathogenesis. The hypothesis of an inefficient clearance of the endometrial cells from the peritoneal cavity has been proposed [161, 162] , due to peripheral and peritoneal NK cells failure to eliminate autologous dendritic cells [163] expressing self-endometrial antigens what results in their presentation to autoreactive T cells and the production of auto-antibodies [164] .
Lymphocytes are also involved in various cytokines production with potential role in endometriosis development. Peritoneal fluid Th2 cells were shown to stimulate the secretion of IL-4 and IL-10, mainly by peritoneal macrophages, resulting in an aberrant suppression of cell-mediated immunity what may enable implantation of endometrial cells in peritoneum [165] .
Moreover, the NK cell-mediated cytotoxicity, manifested by lymphocytes adherence to endometrial cells by LFA-1 -ICAM-1 pathway and their presentation as targets to NK cells, may fail in endometriosis. This finding has been demonstrated by an in vitro study [166] and later on confirmed by flow cytometry in human endometriosis [167] . According to this possible mechanism involved in endometriosis pathogenesis, sICAM-1 may bind to LFA-1 expressing lymphocytes, preventing endometrial cells recognition by lymphocytes and, furthermore, preventing NK-mediated cytotoxicity [166] . Consequently, endometriosis is characterized by the inability of immune cells to send death signals to endometrial cells and/or the ability of ectopic endometrial fragments to avoid cellular death due to an increased expression of anti-apoptotic molecules [168] .
TNF-a, a pro-inflammatory cytokine, is also produced by macrophages, exhibiting elevated levels in the peritoneal fluid [36, 169] and serum [169] in endometriosis patients. It has been shown recently that TNF-a-induced IKKb complex activation leads to the initiation and progression of endometriosis, by enhancing the viability of the ectopic epithelial cells but not eutopic epithelial cells, or endometrial stromal cells [170] .
MIF, another cytokine, shows a high level in the peritoneal fluid, in circulation, and in peritoneal macrophages, its secretion being induced in endometriosis by estrogens [171] . MIF stimulates endothelial cell proliferation, endometriotic lesion survival, expression of PGE2, COX-2, VEGF, IL-8, MCP-1, aromatase, and reciprocally stimulates TNF-a in endometrial cells [56, 152, 158, 172] . ISO-1, MIF antagonist, is responsible for a significant reduction in endometriotic lesion size, in experimental models, by inhibiting cell adhesion, tissue remodeling, angiogenesis, and inflammation, in addition to alteration of the balance between pro-and anti-apoptotic factors [155] . 
Hormones and hormone-like substances in the pathogenesis of endometriosis
Steroid hormones play an important role in endometrial physiology and their unbalanced activity is involved in endometrial pathology, including endometriosis.
In this regard, it has been demonstrated that the driving factor of the production of cytokines in endometriosis is the altered responsiveness to progesterone, showing a characteristic very low expression of progesterone receptor A (PR-A) and the absence of PR-B in mice models [173] , and in a similar way with decreased PR-B/A ratio and reduced PR-B immunoreactivity, demonstrated in human endometriosis [78, 174] .
Supplementary, the increased local estrogen levels further drive the endometriotic lesion phenotype and increased cytokine expression and apoptosis in a murine endometrium [175] . Hormonal dependence in endometriosis is demonstrated by an increased ER-b expression (approximately 100 times more than that of eutopic endometrium), due to altered methylation in the ESR2 gene promoter [174] . ER-b overexpression suppresses ER-a expression and, furthermore, leads to an abnormally high ER-b/ER-a ratio, which is responsible to a reduced expression of PR and an increased COX-2 expression [38, 39, 77, 171]. ER-b activation results in the stimulation of MIF expression and production in the cultures of human endometrial cells [171] . In experimental endometriosis model, ER-b seems to be responsible for the inhibition of endometriotic cell apoptosis and the increased cytokine production, such as MCP-5, IL-1b, and IL-16, which results in enhanced cell adhesion and proliferation [175] .
Stimulation of COX-2 activity by MIF results in the increased secretion of PGE2 that is considered a master regulator of endometriosis on the basis of its pro-inflammatory actions documented by its elevated levels in human endometriotic tissue and in peritoneal fluid [158, 176] .
Angiogenesis in endometrial tissue
The angiogenic activity is stimulated in endometriosis by a large spectrum of angiogenic factors such as IL-1 [177] , IL-6, IL-8, VEGF [178] , ENDO-I (an endometrial haptoglobin homologue) [179] , angiogenin [180] , pleiotrophin, midkine [181] , TNF-a [182] , PGF [183] , angiopoietin [25] , and glycodelin [26, 27] . Moreover, in endometriosis the physiological angiogenic activity is supplemented by the co-existence of pathologic angiogenesis, immune suppression, and immune activation [184] . Environmental factors, such as dioxins, may be also responsible for an increased angiogenesis [60] .
VEGF-A role is demonstrated by its increased concentrations in serum, peritoneal fluid, and endometrium of patients with endometriosis [17, 185, 186] . For instance, it was found that high levels of serum VEGF-A are useful for the diagnosis and follow-up in advanced stage of endometriosis [17] . Moreover, it was confirmed that the expression of VEGF-A gene was higher in peritoneal endometriosis compared with normal peritoneum [185] .
One of the tools to assess angiogenesis in endometriosis is the measurement of vascular surface density (microvessel density or mean vascular density, MVD) [187] . An in vivo study, using transvaginal color and power Doppler, has demonstrated the correlation between high MVD and pelvic pain in patients with endometriosis [188] . This finding has been validated by immunohistochemical evaluation of CD34-labeled vessels [24, 188] . Although the active lesions showed a high mitotic index and increased MVD in implants, no significantly increased VEGF expression has been found, suggesting the involvement of other angiogenic factors [24] .
Apoptosis
An apoptosis evasion mechanism has been demonstrated in endometriosis, allowing the development of ectopic implants. This particular mechanism has been characterized by increased expression of anti-apoptotic Bcl-2 along with decreased pro-apoptotic Bax expression [99, 100] . Apoptosis may be also regulated by Fas ligand (FasL) by its binding to cell membrane receptor, Fas. FasL binding results in extrinsic (autocrine or paracrine) induction of apoptosis [189] . It was found that in cultured human endometrial stromal cells IL-8 up-regulated FasL protein expression and decreased apoptosis rate [189] , the latter found in human endometrial tissue was associated with increased mRNA levels of survivin and MMPs [101] .
Multistep development of endometriosis
The results of numerous studies in humans and in animal models allowed proposing a multistep etiopathogenic mechanism of endometriosis [50, [190] [191] [192] [193] [194] [195] [196] [197] .
Following retrograde menstruation which is the triggering phenomena responsible for an increased number of endometrial cells in peritoneal fluid, other associated mechanisms are contributing to immune surveillance failure (i.e. decreased NK cytolytic [46] and cytotoxic [162, 198] activity, ICAM-1 secretion [35] ), that is further supplemented by decreased apoptosis of endometriotic cells [175, 199] . The next stage is marked by the localization of refluxed endometrial cells in the peritoneal cavity, followed by increased number of activated macrophages, increased secretion After the ectopic implantation and invasion, other processes take place: stimulation of angiogenesis due to enhanced levels of IL-1, IL-6, and VEGF, decreased immune surveillance, increased presentation of self-antigens by dendritic cells, T and B cells activation, elevated levels of autoantibodies, and positive feedback enhancing inflammation and immune responses [141] .
These cascading events are responsible by the continuous development and persistence of endometriosis. The available evidence strongly suggests that pivotal factors can be attributed to cytokines and growth factors produced by activated macrophages which not only fail to eliminate but promote development of endometriosis.
Endometriosis versus carcinogenesis
Relationships between endometriosis and malignancy
As early as in 1927, the idea linking endometriosis with malignant transformation has been hypothesized [203] , mainly for the ovarian location. Since then, numerous studies have demonstrated the overlap of definition criteria of malignant phenotype with those of endometriosis. Results of meta-analyses revealed their increased association [204, 205] .
Clinicopathological, molecular, and genetic evidences support the hypothesis of endometriosis as a neoplastic process, with a potential to malignant transformation. The first evidence is that of the common features shared by these entities that are both able to disseminate, to invade, and to form distant implants [206] . Moreover, a significant association of endometriosis with clear cell and endometrioid ovarian carcinomas has been reported [87, 95, 103, 104, 106, [207] [208] [209] [210] [211] , e.g. 30-55% and 30-40%, respectively [206] . Furthermore, an increased incidence of concurrent primary malignancy, i.e. endometrial carcinoma, in endometriosis-associated ovarian malignancies suggests common molecular pathways in both locations [212] . A plethora of phenomena are common in sporadic cancer and endometriosis, being determined by complex interactions between hereditary polygenic alleles of low penetrance (polymorphism), acquired genetic alterations, leading to a "signature" of mutations, and microenvironment "permissive" factors, expressed by hormonal influences and chronic inflammation [44, 210, 212] . The current molecular techniques of genetic, transcriptomic and proteomic profiling allow for better characterization of correlations between genetic and local milieu alterations and transition process from normal endometrium to malignant transformation.
A large spectrum of tumors and tumor-like conditions associated with endometriosis has been described, such as polypoid endometriosis, benign tumors (such as endometrioid adenoma, adenofibroma, cystadenofibroma, and cystadenoma), premalignant changes (i.e. atypical endometriosis) (Fig. 1C) , borderline tumors (e.g. endometrioid cystic adenofibroma and endometrioid cystadenofibroma), and malignant tumors, such as endometrioid adenocarcinoma (Fig. 1D) , with squamous elements or with clear cell elements, low-grade and high-grade stromal sarcoma, and malignant tumors with mixed components (i.e. adenosarcoma and carcinosarcoma) [109, 206, [212] [213] [214] [215] .
Another criterion in favor of a relationship between endometriosis and malignancies is that endometriosis consists of a monoclonal tissue development, acquiring many of the cellular characteristics of malignant transformation [4] . Furthermore, the analysis of common features of endometriosis and tumors has revealed that endometriosis can be regarded as an estrogen-dependent neoplasm with an estrogen-induced signaling mechanism characterized by increased production of estrogens [38, 39] , increased P450 cytochrome aromatase activity [171] , increased activity of StAR [156] , increased PGE2 production [156, 158] , increased estrogen responsivity by ER-b overexpression, decreased ER-a expression and abnormal high ER-b: ER-a ratio [76, 77] , decreased expression and responsivity of PR [78] , and hereditary genetic polymorphism of drug-metabolizing enzymes [216, 217] .
It is also widely recognized that in both endometriosis and cancer, there is co-existence of pathologic angiogenesis [218] . Importantly, an increased MMPs expression associated to deregulation of the intercellular adherence signaling is identified both in endometriosis pathogeny and in carcinogenesis.
The current knowledge is that two pathways seem to be involved in endometriosis and its potential progression toward neoplasia: either malignant transformation, probably by an atypical transition stage, either the common precursor mechanism or predisposing factors are shared by both processes, with a consecutive molecular divergence [219] www.fhc.viamedica.pl recent histopathological data confirm the possibility of transition due to identification of an atypical stage and frequent association of ovarian cancer to atypical endometriosis. The significance of borderline tumors is currently regarded as a part of endometriosis-associated ovarian carcinoma spectrum [206, 214, 215] . Moreover, recent evidences indicate that patients with endometriosis have a significant risk for endometrial cancer, mainly endometrioid and clear cell subtypes [220] .
Endometriosis as a precursor lesion
In endometriosis pathogenesis, an important role has to be attributed to polygenic susceptibility, which implies a metabolic, endocrine, and immune associations, responsible for the increase of the number of endometrial cells and/or immune surveillance decrease and by specific qualities of endometrial cells from the peritoneal fluid and/or pelvic inflammation [221] [222] [223] . Furthermore, the progressive accumulations of genetic alterations of tumor-suppressing genes and oncogenes are probably responsible for endometriosis development and its possible association with the development of malignancies [87-89, 92, 107, 224, 225] .
In numerous studies it was shown that the genetic polymorphism is predisposing either to endometriosis (e.g. of ICAM-1 or gene promoters of IL-6 and IL-10), or to cancer (of genes encoding IL-6, IL-8, TNF-a, NFkB-1, and PPAR-g) [52, 216, 225, 226] . Moreover, the processes involved in endometriosis development are supplemented by genomic instability which contributes to the transition to the stage of atypical endometriosis. Mutations of genes linked to carcinogenesis have been also identified in endometriosis, such as alterations of tumor suppression genes [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] , inactivation of DNA mismatch repair genes, by hypermethylation [93] , and LOH [87, 107, 109, 219] . Thus, the next step represented by a transition or pre-malignant phase, is characterized by 4q, 5q, 6q, 9p, 11q, 22q, 10q23. [227] [228] [229] . Furthermore, somatic mutations in TSG germinal lines may add support to this hypothesis [107, 224, 225] .
Considering the panel of genetic mechanisms which act synergistically contributing to cancer genomic instability, with variable overlapping contribution, such as oncogenic activity, TSG inactivation, DNA repairing enzymes anomalies, inactivation of checkpoints genes of cellular cycle assembly, and telomere dysfunctions, some of these pathways have to be also detected in precursor lesions. As expected, premalignant lesions (atypical endometriosis) are characterized by several mutations of tumor suppressor genes, oncogenes, CAMs, and furthermore LOH and inflammatory immunomodulation [198] . Table 2 summarizes the arguments in favor of a common genotype in endometriosis and endometriosis-associated ovarian cancers.
Novel approaches and therapeutic agents in endometriosis
Acknowledging the role of hormonal stimulation in endometriosis, a panel of drugs has been developed to modulate the excessive ovarian estrogens synthesis, e.g. oral contraceptives (containing an estrogen component, such as ethinyloestradiol, mestranol, estradiol or its pro-drug estradiol valerate, combined with a progestogen, such as levonorgestrel, norethisterone, drospirenone, gestodene, desogestrel, nomegestrol, dienogest or cyproterone) [248] , gestagens [249] , and danazol ((17a)-Pregna-2,4-dien-20-yno[2,3-d] isoxazol-17-ol) [19] . Danazol has hormonal action, by antigonadotropic action, androgenic activity, and interaction with ERs and is also considered a powerful immunologic tool in endometriosis, due to its ability to decrease immunoglobulins, C3 and C4 complement, auto-antibodies against phospholipid antigens, and CA-125 levels, as well as its capacity to suppress lymphocyte proliferation, along with suppression of IL-1 and TNF-a production by macrophages [19] .
The analysis of the common characteristics of carcinogenesis and endometriosis development, such as sustained proliferative capacity, evasion of growth suppressors and of immune destruction, replicative immortality, involvement of tumor-promoting inflammation, angiogenesis, invasion and metastasis, genome instability and mutations, resistance to cell death stimuli, and deregulation of cellular energetics, lead to the enlargement of the therapeutic arsenal by targeting common molecules and molecular pathways involved in endometriosis and endometriosis-related ovarian cancers [96, 102, 208, 230, [250] [251] [252] [253] [254] [255] [256] .
Thus, by comparing the similar molecular pathways identified in both endometriosis and other cancers (i.e. breast, ovary, and endometrium cancers), a series of anti-cancer agents are currently in different clinical trials for endometriosis therapy, awaiting their validation. Table 3 documents the progress achieved in endometriosis by therapy with anti-cancer agents [102, 201, 208, [230] [231] [232] [233] [250] [251] [252] [253] [254] [255] [256] [257] [258] [259] . Novel therapeutic approaches applicable in endometriosis show at least five categories of anti-cancer agents that may relate Hormonal status is addressed by administration of aromatase inhibitors (letrozole, anastrozole) which block the conversion of androstendione to estrone, creating a low estrogen environment [260] . Another approach is to modulate ER activity, either by ER-b ligands (CLI or OBHS) already used in clinical practice [261] or by selective ER modulators (arzoxifene, bazedoxifene [262] , raloxifene [263] ) which are still tested in experimental models. In the regulation of progesterone action, P4 antagonists (mifepristone, RU-486 [264] ) and selective PR modulators (asoprisnil, BAY 1002670) [265] , PF-02413873 [266] ) have shown promising results in endometriosis therapy in either clinical application or in rodent experiments. In order to eliminate the systemic side effects, Mirena coil (levonorgestrel-releasing intrauterine system) has been added to the therapy [267] . In an attempt to regulate the hypothalamic stimulation of the hormonal axis, Gn-RH agonists (elagolix [268] , leuprolide, nafarelin, buserelin, goserelin, triptorelin [269] , abarelix [270] ) showed regression of human endometriotic lesions related to hypoestrogenism and, possibly, to a supplementary anti-angiogenic activity.
Anti-angiogenesis has been considered as an alternative therapeutic approach showing efficacy in endometriosis reduction without side effects on fertility or toxicity profiles. Several anti-angiogenic agents have been tested in experimental endometriosis. In mouse models, rapamycin clearly reduced endometriotic implants, along with diminished VEGF expression and decreased MVD [271] ; in the nude mouse model endostatin affected expression of VEGFR2 and/or VEGF isoforms and decreased HIF-1a expression [272] , while angiostatin showed a complex mechanism of the inhibition of blood vessel development [273, 274] ; anginex demonstrated anti-angiogenic activity in mouse model of endometriosis [274] . In a rat endometriosis model, bevacizumab, VEGF-neutralizing monoclonal antibody, was shown to increase apoptosis [275] . Other drugs with anti-angiogenic effects confirmed in experimental endometriosis are celecoxib, a COX-2 inhibitor [276] , and non-toxic fumagillin analogs, semisynthetic derivatives of a natural antibiotic, Aspergillus fumigatus [274] . The results of these Tumor suppressor ARID1A ± BAF250a mutation [94, 95, 96, 105, 209, [230] [231] [232] [233] expressed [105, 233] expressed [94, 95, 96, 105, 209, [230] [231] [232] PTEN somatic mutations [87-89, 93, 227, 228, 234] expressed [88, 89, 93, 227, 228] expressed [87, 88, 227, 228, 234] PIK3CA mutations [96, 104, 207] early event in endometriosis transformation [104] expressed [96, 104, 207] TP53 [90-92, 107, 213, 228, 229] expressed (late stages) [91, 92, 107, 228] expressed (advanced stages) [90, 213, 228, 229] Oncogene KRAS ±BRAF [103, 235] expressed (atypical endometriosis) [103, 235] expressed (mucinous type) [103] CTNNB1/WNT/b-catenin [72, 227, 236, 237] expressed (atypical endometriosis) [72, 237] expressed [227, 236] miRNA profiling miRNA instability [238] [239] [240] [241] [242] [243] [244] www.fhc.viamedica.pl experimental studies represent provide hope for the application of anti-angiogenic therapies in human endometriosis. Promising novel anti-endometriosis drugs are represented by the pro-apoptotic agents, such as apoptosis inducer (arcyriaflavin) [277] , apigenin [278] , NF-kB inhibitor (PDTC), and proteasome inhibitors (bortezomib) [279] that were tested on human cell lines and rat models.
Final remarks
Due to endometriosis heterogeneity, attributed to genomic and proteomic variability, expressed by variable anatomic location, number, size and duration of implants, carcinogenesis associations, numerous subtypes of endometriosis have been described. Current trends in genomic and proteomic approaches are useful for a deeper understanding of endometriosis pathogeny and its malignant transformation, a better (re)classification, and a higher potential identification of new therapeutic targets. The putative biomarkers such as P450 aromatase, IL-6, TNF-a, and anti-endometrial cells autoantibodies have been proposed.
Nowadays, the therapy is limited by high frequency of recurrences and the impossibility to preserve 
